Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis
Brief Summary: Primary Objective:

To evaluate the efficacy of dupilumab (SAR231893/REGN668) in the treatment of bilateral Nasal Polyposis (NP) by assessment of the endoscopic nasal polyp score (NPS) in comparison to placebo.

Secondary Objectives:

To evaluate effect of dupilumab with regards to:

* symptoms of sinusitis,
* sinus computed tomography (CT) scan,
* NPS in the sub-group of participants with co-morbid asthma,
* Safety and tolerability.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for dupilumab), Drug: Mometasone furoate nasal spray | Arm Label: Dupilumab 300 mg QW; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Mometasone furoate nasal spray | Intervention Type: DRUG; Name: Placebo (for dupilumab); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg QW | Intervention Type: DRUG; Name: Mometasone furoate nasal spray; Assigned to Arm(s): Dupilumab 300 mg QW, Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo (for Dupilumab 200 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Placebo (for Dupilumab 300 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Inhaled corticosteroid (ICS) therapy; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Albuterol/Salbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Levalbuterol/Levosalbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w
D: Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab SAR231893 (REGN668), Drug: Mometasone furoate nasal spray | Arm Label: Dupilumab 300 mg q2w then q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab SAR231893 (REGN668), Drug: Placebo, Drug: Mometasone furoate nasal spray | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Mometasone furoate nasal spray | Intervention Type: DRUG; Name: Dupilumab SAR231893 (REGN668); Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg q2w then q4w | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dupilumab 300 mg q2w then q4w, Placebo | Intervention Type: DRUG; Name: Mometasone furoate nasal spray; Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg q2w then q4w, Placebo

Answer: A